Another approach has been described to overcome cancer-mediated immunosuppression, involving the reactivation of hyporesponsive tumor-specific T cells by supplying T-cell growth factors (IL-15 and IL-7) or costimulatory agonists (anti-4-1BB and anti-OX40) [101]. This evidence concerns the gene IL7 and neoplasm.